PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM CNS STIMULANT AMPHETAMINES SYMPATHOMIMETICS BLOCK THE REUPTAKE OF NOREPINEPHRINE AND DOPAMINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND NARCOLEPSY MONOAMINE TRANSPORTER BLOCKER
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM SYMPATHOMIMETICS CAUSES THE RELEASE OF ENDOGENOUS NOREPINEPHRINE MYDRIATIC EFFECT PROVIDES DIMINISHED PUPIL RESPONSIVENESS TO LIGHT ADRENERGIC AGENT
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM ADRENERGIC AGENT SYMPATHOMIMETICS CAUSES THE RELEASE OF ENDOGENOUS NOREPINEPHRINE MYDRIATIC EFFECT PROVIDES DIMINISHED PUPIL RESPONSIVENESS TO LIGHT
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex